Oxford BioDynamics (LON:OBD) Shares Up 22.2% – Still a Buy?

Oxford BioDynamics Plc (LON:OBD) rose 22.2% during trading on Wednesday . The company traded as high as GBX 0.65 ($0.01) and last traded at GBX 0.61 ($0.01). Approximately 332,737 shares traded hands during mid-day trading, a decline of 93% from the average daily volume of 4,561,860 shares. The stock had previously closed at GBX 0.50 ($0.01).

Oxford BioDynamics Stock Up 25.8 %

The business has a 50 day simple moving average of GBX 1.11 and a 200 day simple moving average of GBX 3.28. The company has a debt-to-equity ratio of 370.22, a current ratio of 0.68 and a quick ratio of 2.80. The stock has a market cap of £1.96 million, a PE ratio of -10.48 and a beta of 0.42.

About Oxford BioDynamics

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.